Results 41 to 50 of about 3,369,625 (303)

Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database

BMC Cancer, 2021
Background Hepatocellular carcinoma (HCC) incidences have been increasing in the United States. This study aimed to examine temporal trend of HCC survival and determine prognostic factors influencing HCC survival within the U.S. population.
Jingli Ding, Zhili Wen
doaj   +1 more source

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

The next steps in improving the outcomes of advanced ovarian cancer [PDF]

, 2015
Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication.
Blagden, S, Fotopoulou, C, Gabra, H, Openshaw, MR   +3 more
core   +1 more source

Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2015
Broglio and Berry (2009) examined the impact of survival postprogression (SPP) on overall survival (OS) when progression-free survival (PFS) was used to assess treatment effect in metastatic cancer. Their simulation studies found no statistical difference in OS because of dilution effect from SPP, although there was a statistical difference in PFS ...
Morita, S, Sakamaki, K, Yin, G
openaire   +4 more sources

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer

Breast Cancer: Targets and Therapy, 2022
Hanan Almasri,1 Ayah Erjan,1 Hebah Abudawaba,1 Khaled Ashouri,2 Sara Mheid,1 Anoud Alnsour,1 Hikmat Abdel-Razeq2,3 1Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan; 2Department of Internal Medicine, King Hussein Cancer Center,
Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H   +6 more
doaj  

Evaluating overall survival and competing risks of survival in patients with early‐stage breast cancer using a comprehensive nomogram

Cancer Medicine, 2020
Background Patients with early‐stage breast cancer (BC) live long but have competing comorbidities. This study aimed to estimate the effect of cancer and other causes of death in patients with early‐stage BC and further quantify the survival differences.
Yan‐Bo Xu, Hong Liu, Qi‐Hua Cao, Jia‐Li Ji, Rong‐Rong Dong, Dong Xu   +5 more
doaj   +1 more source

Myeloma multiplex treatment and overall survival

Macedonian Pharmaceutical Bulletin, 2021
The Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines.
Svetlana Krstevska Balkanov, Sanja Trajkova, Sonja Genadieva Stavric, Aleksandra Pivkova Veljanovska, Marija Popova Labacevska, Dejan Spasovski, Irena Rambabova Bushljetik, Goce Kalcev, Irina Panovska Stavridis   +8 more
openaire   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source